Ochre Bio alum's new neuro siRNA startup Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 1 October, 2025

Healthcare's #1 must-attend innovation event. Join industry leaders and stakeholders converge to ignite change, form strategic partnerships, and explore transformative solutions for a healthier tomorrow. sponsored by HLTH, Inc.

presented by De­sign It Right: Eval­u­at­ing AAV Man­u­fac­tura­bil­i­ty Through Mol­e­c­u­lar and Up­stream Op­ti­miza­tion

news What we do and don’t know after the White House’s deal with Pfizer FDA approves Novartis' BTK inhibitor for chronic hives After building Ochre Bio, Jack O'Meara's newest biotech raises $21M for neuro siRNAs Vertanical unpacks Phase 3 success for cannabis-based painkiller

Oct 02 10:30am ET Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery sponsored by Lilly Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

Big Pharma is doubling down. Startups are going all in. Who’s actually making AI work in drug R&D? Join the debate with expert discussions and insights you won’t want to miss. Register today.

endpoints pharma Trump announces ‘most favored nation’ drug price deal with Pfizer After months of investigation on drug tariffs, Trump seals new levies with a social media post ‘Likely’ government shutdown threatens to stress an already depleted FDA Under new CEO, Novo ends heart failure partnership with Japanese biotech

in case you missed it 1. Merck makes the case for PAH drug Winrevair in patients with earlier disease 2. Metsera’s new obesity data mean Pfizer has side effect and efficacy questions to answer 3. Star gets $125M Series D as it begins Phase 3 in bleeding disorders 4. Opus says Luxturna-like gene therapy for ultra-rare disease boosted vision in teens 5. AnaptysBio plans to split its pipeline from its royalty assets into two publicly traded companies 6. Crystalys lands $205M to bring gout drug first marketed in Japan to the US and Europe 7. News Briefing Barinthus’ reverse merger with private biotech; Sutro to lay off 33% of employees 8. Brussels raids Sanofi in flu vaccine antitrust probe